Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 16;40:196. doi: 10.1186/s13046-021-01984-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 4 — The levels of mutated ctDNA in UM patients and patients with uveal nevi correlated with the stage of disease progression and with the presence of risk factors for malignant transformation, respectively. A. UM patients: levels of GNA11, GNAQ and PLCβ4 mutated ctDNA (molecules/mL of plasma) are shown in dark blue, red and green, respectively, and %FA of GNA11, GNAQ and PLCβ4 is shown in light color (the table shows the mutation status in the analyzed loci). B. Nevi: levels of ctDNA molecules/mL of plasma (dark) and %FA (in light color) in patients (the table shows the mutation status in the analyzed loci). Note that in all patients, only a GNAQ mutation was detected. P:plasma. S:serum. C. Left panel: the %FA obtained with the UM samples were plotted against the T category of the AJCC staging, which displayed a significant positive correlation (r = 0.69, P = 0.008). Right panel: The %FA obtained with the UM samples were plotted against tumor thickness (mm); no correlation was found (r = 0.38, P = 0.079). D. The levels of mutated ctDNA in plasma samples obtained from patients with nevi were plotted against the number of risk factors in every patients, which displayed a significant positive correlation (r = 0.92, P < 0.0001). E Left panel: Scatter plot depicting the levels of mutated ctDNA in the plasma of UM patients and patients with nevi displaying or not risk factors for malignant transformation, and serum of healthy blood donors. Note the increased levels of ctDNA that accompany increased risk factors. The table (on the right) depicts the comparisons used and the levels of significance for differences (P value)